People with severe and difficult-to-treat sarcoidosis can safely switch from Remicade (infliximab) or its biosimilar Inflectra, to another biosimilar called Flixabi and maintain similar clinical benefits, a study reports. Six months after switching, none of these patients had stopped…
News
Long before COVID-19 changed the world, organ transplant recipients were wearing masks to shield themselves from airborne threats. Immunosuppressive medicines, which often are a lifelong after a transplant, require these people to add an extra layer of protection against viruses as common as a cold or as dangerous as COVID. They…
The Foundation for Sarcoidosis Research (FSR) is holding a two-day virtual patient education summit focused on providing relevant medical content on sarcoidosis, patient and care-partner perspectives, and updates on current and future research in the field. To attend the summit, set for June 12–13, patients and caregivers can…
A professor at Northwestern University has been awarded a $50,000 American Thoracic Society (ATS)/Mallinckrodt Pharmaceuticals Research Grant to study the role of immune macrophages in the development of sarcoidosis. Sarcoidosis is a complex immune disease characterized by the accumulation of immune cells such as macrophages,…
A short, in-hospital exercise program was found to decrease the levels of fats, or lipids, in the blood of people with sarcoidosis and to improve their physical health. In fact, researchers said that changes in the lipid profile could potentially be used to determine how well a patient is…
More than half of the people with rare diseases and their caregivers, asked in a survey, were undecided or less than willing to be vaccinated for COVID-19 if a vaccine was approved under emergency use authorization instead of the routine process, the EveryLife Foundation for Rare Disease reports. These findings…
The EveryLife Foundation for Rare Diseases is accepting applications for a scholarship program that aims to help adults with a rare disease pursue personal goals through training and education. For a second year, the #RAREis Scholarship Fund — supported by Horizon Therapeutics – will award 35 one-time scholarships, each…
aTyr Pharma, which is developing a candidate therapy for pulmonary sarcoidosis called ATYR1923, has appointed Andrea Wilson — a sarcoidosis patient and advocate who co-founded the Foundation for Sarcoidosis Research (FSR) — as a patient advisor. “We are pleased during Sarcoidosis Awareness Month to welcome Andrea, a…
As anyone affected by a rare disease knows, treating the illness while trying to go about everyday life is an expensive undertaking. But exactly how expensive — in terms of direct and indirect costs across rare disease populations — might still come as a surprise: almost…
From taking part in a virtual endurance challenge to joining in a virtual cooking class, to watching several speaker presentations, advocates are set to mark Sarcoidosis Awareness Month, observed each April. World Sarcoidosis Day will be celebrated on April 13. Awareness and education are crucial to increasing the recognition,…
Recent Posts
- To scoot or not to scoot: Using a mobility aid with a dynamic disability
- Mobile app for breathing meditation may reduce sarcoidosis fatigue
- New report highlights unmet needs and treatment burdens in sarcoidosis
- Cardiac sarcoidosis symptoms at diagnosis help predict long-term risk
- Methotrexate is safer second-line sarcoidosis treatment than MMF
- A holiday gift guide for your loved one with sarcoidosis
- FSR gathers global leaders to drive progress in sarcoidosis research
- New genetic clues connect sarcoidosis with lung cancer risk
- When patients and caregivers swap roles, empathy usually follows
- Underdiagnosis of cardiac sarcoidosis leaves people at risk